Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6671785 | 0.87 | ESR1 (0.40) | PPARGPPARAALDH1A1MAPTKMT2A | |
| SCHEMBL14947768 | 0.86 | PPARG (0.41) | PPARGPPARAALDH1A1HPGDCTBP2 | |
| SCHEMBL3955417 | 0.85 | PPARG (0.45) | PPARGPPARAALDH1A1HPGDCTBP2 | |
| SCHEMBL27305323 | 0.84 | PPARG (0.44) | PPARGPPARAALDH1A1HPGDCTBP2 | |
| SCHEMBL15772413 | 0.83 | KMT2A (0.42) | PPARGALDH1A1HPGDMAPTKMT2A | |
| SCHEMBL27556049 | 0.81 | ALDH1A1 (0.49) | PPARGPPARAALDH1A1MAPTKMT2A | |
| SCHEMBL3955410 | 0.80 | KMT2A (0.65) | PPARGPPARAALDH1A1MAPTKMT2A | |
| SCHEMBL7437418 | 0.80 | KMT2A (0.58) | PPARGPPARAALDH1A1HPGDCTBP2 | |
| SCHEMBL7435174 | 0.79 | MMP13 (0.44) | PPARGPPARAALDH1A1HPGDCTBP2 | |
| SCHEMBL7406460 | 0.79 | PPARG (0.43) | PPARGPPARAALDH1A1HPGDCTBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022075354-A1 | A METHOD FOR OBTAINING AN INDEX FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE (AD) | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2022-04-14 | — | — | WO | claimed |
| US-20260137717-A1 | TREATMENT FOR GINGIVITIS | THE UNIVERSITY OF MELBOURNE (AU) | 2026-05-21 | — | — | US | disclosed |
| US-20260115109-A1 | STABILIZED STANNOUS COMPOSITIONS | THE UNIVERSITY OF MELBOURNE (AU) | 2026-04-30 | — | — | US | disclosed |
| US-12569417-B2 | Compositions and methods for promoting mineralization | THE UNIVERSITY OF MELBOURNE (AU) | 2026-03-10 | — | — | US | disclosed |
| US-12551417-B2 | Stabilized stannous compositions | THE UNIVERSITY OF MELBOURNE (AU) | 2026-02-17 | — | — | US | disclosed |
| US-12303548-B2 | Complexes for treating sensitivity | THE UNIVERSITY OF MELBOURNE (AU) | 2025-05-20 | — | — | US | disclosed |
| US-20250152666-A1 | COMPLEXES FOR TREATING SENSITIVITY | THE UNIVERSITY OF MELBOURNE (AU) | 2025-05-15 | — | — | US | disclosed |
| WO-2025097213-A1 | COMPOSITIONS AND METHODS FOR TREATING HALITOSIS | THE UNIVERSITY OF MELBOURNE (AU) | 2025-05-15 | — | — | WO | disclosed |
| US-20250152482-A1 | STABILIZED STANNOUS COMPOSITIONS | THE UNIVERSITY OF MELBOURNE (AU) | 2025-05-15 | — | — | US | disclosed |
| US-12239723-B2 | Stabilized stannous compositions | THE UNIVERSITY OF MELBOURNE (AU) | 2025-03-04 | — | — | US | disclosed |
| WO-2001045746-A2 | METHODS AND COMPOSITIONS FOR PROLONGING ELIMINATION HALF-TIMES OF BIOACTIVE COMPOUNDS | GENENTECH, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1105475-A1 | TISSUE FACTOR PROTEIN VARIANTS WITH INCREASED AFFINITY FOR COAGULATION FACTOR FVII/FVIIA | Genentech, Inc. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001010892-A2 | PEPTIDE ANTAGONISTS OF FACTOR VIIA | GENENTECH, INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| WO-2001001749-A2 | FVIIa ANTAGONISTS | GENENTECH, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000078801-A2 | INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES | GENENTECH, INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000068363-A2 | ELASTASE VARIANTS AND SUBSTRATES | GENENTECH, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| US-6028055-A | USE IN TREATMENT OR PROPHYLAXIS OF VARIOUS PATHOLOGICAL CONDITIONS ASSOCIATED WITH WATER OR ELECTROLYTE IMBALANCE | GENETECH, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-2000004148-A1 | TISSUE FACTOR PROTEIN VARIANTS WITH INCREASED AFFINITY FOR COAGULATION FACTOR FVII/FVIIA | GENENTECH, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
| EP-0939770-A1 | RECEPTOR SPECIFIC BRAIN NATRIURETIC PEPTIDE (BNP) | Genentech, Inc. (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998017690-A1 | RECEPTOR SPECIFIC BRAIN NATRIURETIC PEPTIDE (BNP) | GENENTECH, INC. (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137717-A1 | TREATMENT FOR GINGIVITIS | ACP3, FIBP, FGF23 | PPARG 508/4885PPARA 1520/4885ALDH1A1 4794/4885 |
| US-20260115109-A1 | STABILIZED STANNOUS COMPOSITIONS | CHERP, FIBP, ACP3 | PPARG 2518/4885PPARA 2950/4885ALDH1A1 4733/4885 |
| US-12551417-B2 | Stabilized stannous compositions | CHERP, CA3, CA2 | PPARG 2686/4885PPARA 3006/4885ALDH1A1 4715/4885 |
| US-12569417-B2 | Compositions and methods for promoting mineralization | CA3, FIBP, ACP3 | PPARG 1463/4885PPARA 2816/4885ALDH1A1 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.